Evidence map›Paper›PMID 33515112›Full record

ArticleJournal of molecular histology2021

RHBDD1 silencing inhibited cell growth and invasion of non-small cell lung cancer by mediating ZEB1/PI3K/AKT signaling pathway.

Zheyuan Xu, Ran Wang, Xu Li, Limin Yang, Hao Peng, Yang Wang, Ping Wang

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of molecular histology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.6field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Zheyuan XuDepartment of Thoracic surgery, The Second Affiliated Hospital of Kunming Medical University, 650101, Kunming, Yunnan, China.
Ran WangMailman School of Public Health, Columbia University, New York, USA.
Xu LiDepartment of Thoracic surgery, The Second Affiliated Hospital of Kunming Medical University, 650101, Kunming, Yunnan, China.
Limin YangDepartment of Thoracic surgery, The Second Affiliated Hospital of Kunming Medical University, 650101, Kunming, Yunnan, China.
Hao PengDepartment of Thoracic Surgery, The First People's Hospital of Yunnan Province, Kunming, Yunnan, China.
Yang WangDepartment of Thoracic surgery, The Second Affiliated Hospital of Kunming Medical University, 650101, Kunming, Yunnan, China.
Ping WangDepartment of Thoracic surgery, The Second Affiliated Hospital of Kunming Medical University, 650101, Kunming, Yunnan, China. pingwang2467@163.com.ORCID http://orcid.org/0000-0003-2956-8700
Kunming Medical University · CNColumbia University · USFirst People's Hospital of Yunnan Province · CN

Funding

Joint Foundation of Science&Technology Department of Yunnan Province and Kunming Medical University 2019FE001(-115)the Foundation from health commission of yunnan province 2018NS0271
6 · The paper itself

Abstract

Rhomboid domain containing 1 (RHBDD1) gene, which was reported to be upregulated in human several cancer, was associated with carcinogenesis. However, the potential biological function of RHBDD1 in non-small cell lung cancer (NSCLC) carcinogenesis remains still not known. In this study, we aimed to investigate the role of RHBDD1 and its underlying molecular mechanism in NSCLC. The gene RHBDD1 expression was detected in NSCLC tissues and matched nontumor adjacent tissues. In vitro experiments, NSCLC cell lines (A549, H1650, H358 and H1299) were performed to investigate the biological function of RHBDD1 and its molecular mechanism. Our findings showed that the mRNA and protein expression levels of RHBDD1 were notably increased in human NSCLC tissues and cell lines, especially in A549 and H1650 cells. Moreover, silencing of RHBDD1 by RNAi notably inhibited NSCLC cell proliferation and increased cell apoptosis. Caspase-3/7 activity was remarkably increased in cells treated with RHBDD1 siRNA. RHBDD1 silencing notably reduced the number of invading cells. Furthermore, our findings showed that silencing of RHBDD1 notably inhibited the mRNA and protein expression levels of ZEB1 in A549 and H1650 cells. The phosphorylation of PI3K and AKT was also remarkably decreased by RHBDD1 silencing. ZEB1/AKT overexpression reversed the effect of RHBDD1 silencing on NSCLC cell growth and invasion. Taken together, our findings indicated that RHBDD1 silencing inhibited cell growth and invasion of non-small cell lung cancer by mediating ZEB1/PI3K/AKT signaling pathway, implying that RHBDD1 was possibly a potential diagnostic and therapeutic target for NSCLC treatment.

Indexed as

Gene SilencingSignal TransductionAgedCarcinoma, Non-Small-Cell LungCell Line, TumorCell ProliferationGene Expression Regulation, NeoplasticHumansLung NeoplasmsMiddle AgedNeoplasm InvasivenessPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktSerine EndopeptidasesUp-RegulationZinc Finger E-box-Binding Homeobox 1Phosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktRHBDD1 protein, humanSerine EndopeptidasesZEB1 protein, humanZinc Finger E-box-Binding Homeobox 1Cell growthInvasionNon-small cell lung cancerRHBDD1ZEB1

Identifiers

PMID33515112
OpenAlexW3125191201

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.